Willie Quinn

Developing immunotherapies to tackle cancer at Bolt Bio.
Husband & Dad.

[Willie Quinn @WPQuinn]

Nice work Justin! Proud to be a part of this @BoltBio team.

[Moffitt Cancer Center @MoffittNews]

Live from #SITC25: Justin Kenkel, PhD (@BoltBio) presents a novel PD-L1–directed Immune Stimulatory Antibody Conjugate (ISAC) that activates both innate and adaptive immunity to fight cancer.

Key takeaways:
• Unlike standard PD-L1 blockers, this ISAC delivers a TLR agonist to PD-L1⁺ myeloid cells, activating macrophages and dendritic cells.
• Induces cytokine release and repolarizes the tumor microenvironment from immunosuppressive to immune-stimulatory.
• Promotes T-cell priming and durable anti-tumor responses in preclinical models.
• Offers a promising strategy to overcome resistance to current PD-1/PD-L1 therapies.

#MoffittSITC25 @sitcancer

[Moffitt Cancer Center @MoffittNews]

Live from #SITC25: Justin Kenkel, PhD (@BoltBio) presents a novel PD-L1–directed Immune Stimulatory Antibody Conjugate (ISAC) that activates both innate and adaptive immunity to fight cancer.

Key takeaways:
• Unlike standard PD-L1 blockers, this ISAC delivers a TLR agonist to PD-L1⁺ myeloid cells, activating macrophages and dendritic cells.
• Induces cytokine release and repolarizes the tumor microenvironment from immunosuppressive to immune-stimulatory.
• Promotes T-cell priming and durable anti-tumor responses in preclinical models.
• Offers a promising strategy to overcome resistance to current PD-1/PD-L1 therapies.

#MoffittSITC25 @sitcancer

[Ivy League @IvyLeague]

BEARS TAKE THE LEAD.

No. 3 @BrownU_WSoccer takes a 2-1 lead following a penalty kick from Lexi Quinn! Just over 40 minutes remain here in Princeton. 🌿⚽️

[Bolt Biotherapeutics @BoltBio]

Today #BoltBio reported financial results for the fourth quarter full year 2023 and provided corporate updates. Learn more: https://t.co/onmwMHB3dC

[Bolt Biotherapeutics @BoltBio]

Our CMO @EdithPerezMD sat down with Danny McCarthy from #IO360 to share insights about the ways Bolt is leveraging the immune system for a better way to treat cancer and discuss her advocacy work in the field. Read the article: https://t.co/IBMiCtrjxj

[Willie Quinn @WPQuinn]

I'm getting ready to run my virtual 5k to support this great cause!

[Bolt Biotherapeutics @BoltBio]

We’re just 1 week away from DONNA Marathon Weekend! #BoltBio is hosting this year’s Curb Crew, and encourages spectators to ring their cowbells loudly to support the runners. Learn more about the @DONNAfoundation and their work to FINISH #breastcancer: https://t.co/Pg7zLkFTRq

[Willie Quinn @WPQuinn]

@BrownU_WSoccer @BrownU_Bears @IvyLeague Great effort. Next year!! Go Brown!

[Willie Quinn @WPQuinn]

I can't wait for this game this afternoon!!!
https://t.co/sJeacW3kEg

[Willie Quinn @WPQuinn]

@BoltBio @Stifel NYC here we come!

[Willie Quinn @WPQuinn]

@rosterloh Congrats Rick! Interesting news.

[Willie Quinn @WPQuinn]

Very excited to showcase preclinical data highlighting the value of combining our BDC-1001 with pertuzumab, and the first look at our Claudin 18.2 ISAC. We're making progress! https://t.co/wbmnAvsfz1

[Bolt Biotherapeutics @BoltBio]

#BoltBio will present updated clinical data from our Phase 1 Dose-Escalation Trial of BDC-1001 for HER2 #breastcancer at the #ESMO23 Congress

Learn more about the presentations:
https://t.co/QeLVXbzsAA
#oncology

[Willie Quinn @WPQuinn]

Proud to be a part of this effort at BOLT!

[Bolt Biotherapeutics @BoltBio]

More than 168,000 people (women AND men) are living in the US with #MBC, and for them, our work is not yet done. See what #TeamBolt is doing about it.
https://t.co/wKjjyJ7E10
#BreastCancerAwarenessMonth

[Bolt Biotherapeutics @BoltBio]

Excited about @US_FDA orphan drug designation for BDC-1001 for the treatment of gastric cancer. We are also actively evaluating it in HER2+ breast, colorectal, and endometrial cancer. Learn more: https://t.co/fpJROZ4K2X
#TeamBolt #immunooncology

[Willie Quinn @WPQuinn]

I liked this article. Growth mindset: let’s learn and improve!

[Inas Abuali, MD @inas_md]

"The propagation of the I-Have-Suffered-So-You-Must-Suffer-Too model of medical education is sadly prevalent."

My latest @ASCO column on #resilience and #MedEd

https://t.co/C046RIlKj3

[Willie Quinn @WPQuinn]

Congrats Brian!!
Deep Genomics Announces the Appointment of Brian O’Callaghan as CEO | Deep Genomics https://t.co/cB6K1VzBaJ

[Willie Quinn @WPQuinn]

Yes, it was nice to be there with Laurie as a special guest.
(And we met @AbbyWambach at the tailgate. :-)
Fun trip!

[Brown Women's Soccer @BrownU_WSoccer]

Got the win in front of some special guests 👀

#EverTrue

[Brown Women's Soccer @BrownU_WSoccer]

Got the win in front of some special guests 👀

#EverTrue

[Bolt Biotherapeutics @BoltBio]

Bolt’s CEO Randy Schatzman spoke to @dslevine of The Bio Report about our science, the immune-stimulating antibody conjugates we’re developing, and our lead program, BDC-1001, which just began Phase 2 trials.

Listen here: https://t.co/HruD7JoLl6

#Immunooncology

[Willie Quinn @WPQuinn]

Great article on some amazing leaders including Bolt’s own @EdithPerezMD !

[Willie Quinn @WPQuinn]

Biopharma leaders paving the way for LGBTQ+ scientists, patients, entrepreneurs and C-suites – Endpoints News https://t.co/cfFJUdrFMn